Please use this identifier to cite or link to this item:
http://publications.jrc.ec.europa.eu/repository/handle/JRC116489| Title: | 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer |
| Authors: | SATHEKGE MIKE; BRUCHERTSEIFER FRANK; KNOESEN OTTO; REYNEKE F; LENGANA T; LAWAL I; BOSHOMANE T; MOKOALA K; VORSTER MARIZA; MORGENSTERN ALFRED |
| Citation: | JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES vol. 50 no. 1 p. S30 |
| Publisher: | ELSEVIER BV |
| Publication Year: | 2019 |
| JRC N°: | JRC116489 |
| ISSN: | 1939-8654 (online) |
| URI: | http://publications.jrc.ec.europa.eu/repository/handle/JRC116489 |
| DOI: | 10.1016/j.jmir.2019.03.091 |
| Type: | Articles in periodicals and books |
| Abstract: | 225Ac- Prostate-specific membrane antigen (PSMA)-617 is a highly promising novel compound for therapy of prostate cancer. A remarkable therapeutic efficacy has been demonstrated in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients, with xerostomia as the main side effect. A promising strategy for minimization of side effects is based on optimization of the dosing regime while maintaining sufficient therapeutic efficacy for several cohorts of patients, including chemotherapy-naïve patients. |
| JRC Directorate: | Nuclear Safety and Security |
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.